Treating difficult crystal pyrophosphate dihydrate deposition disease.
Calcium pyrophosphate dihydrate deposition disease is a common and potentially severe metabolic arthropathy. Early disease (in patients </= 60 years old) requires a search for one of the associated metabolic conditions, particularly hemochromatosis. Treatment is primarily symptomatic (no drug is known to prevent the progression of articular destruction). Nonsteroidal anti-inflammatory drugs and intra-articular or systemic glucocorticoids (in small amounts if use is prolonged) are the most useful treatments. Colchicine can be effective to treat recurring pseudogout, and magnesium can be effective on a preventive basis. Methotrexate showed interesting effectiveness in a small, uncontrolled series, and it can be used in the event of failure of the other treatments.
Announ
Nadia
N
Hôpital Universitaire de Genève, Division de Rhumatologie, 26 Avenue de Beau-Séjour, 1211 Genève 14, Suisse.
Guerne
Pierre-André
PA
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002131:Calcium Pyrophosphate / Q000378:metabolism*; D002805:Chondrocalcinosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D003078:Colchicine / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D017616:Magnesium Compounds / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use; D011339:Probenecid / Q000627:therapeutic use; D014528:Uricosuric Agents / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D017616:Magnesium Compounds; D014528:Uricosuric Agents; D011339:Probenecid; D003078:Colchicine; D002131:Calcium Pyrophosphate; D008727:Methotrexate